There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Springworks Therapeutics (SWTX) and Agenus (AGEN) with bullish sentiments.
Springworks Therapeutics (SWTX)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Springworks Therapeutics today and set a price target of $124.00. The company’s shares closed last Friday at $78.61.
According to TipRanks.com, Burns is a 3-star analyst with an average return of 7.2% and a 38.1% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Black Diamond Therapeutics, and Turning Point Therapeutics.
Currently, the analyst consensus on Springworks Therapeutics is a Strong Buy with an average price target of $112.33.
See today’s analyst top recommended stocks >>
Agenus (AGEN)
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Agenus today and set a price target of $8.00. The company’s shares closed last Friday at $4.03.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 23.2% and a 53.6% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Allena Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agenus with a $7.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
